- About
- Advertise
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Raajit Rampal, MD | Authors
Pharmacotherapy for Myelofibrosis
November 24, 2021
Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.
Treatment Planning and Myelofibrosis
November 15, 2021
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
Symptom Assessments in Myelofibrosis
November 11, 2021
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.
Pathophysiology of Myelofibrosis
November 11, 2021
The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
May 15, 2018
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
April 15, 2018
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.